Related LncRNAs
ID	lncRNA Name	Disease	Method	Sample	Expression pattern	Dysfunction type	Description	PMID	Source
EL1096	PTCSC3	thyroid cancer	microarray, qPCR, Western blot etc.	thyroid tissue, cell lines (PTC)	down-regulated	expression	Expression data from PTC cell lines pinpointed S100A4 as the most significantly downregulated gene in the presence of PTCSC3. S100A4 was upregulated in tumor tissue while PTCSC3 was strongly downregulated. S100A4 transcription was moderately correlated with PTCSC3 expression in unaffected thyroid tissue (r = 0.429, P = .0001), and strongly in unaffected tissue of patients with the risk allele of rs944289. S100A4, VEGF, and MMP-9 were suppressed in the presence of PTCSC3 (P = .0051, P = .0090, and P =.0037, respectively). PTC cells expressing PTCSC3 showed reduction in motility and invasiveness	26274343	Lnc2Cancer
EL1096	PTCSC3	thyroid cancer	qPCR etc.	thyroid cancer tissue, cell lines (BCPAP, FTC133, 8505C etc.)	differential expression	N/A	Following transfection with PTCSC3, all three thyroid cancer cells originating from various pathological types of thyroid cancers demonstrated significant growth inhibition, cell cycle arrest and increased apoptosis. So PTCSC3 as a tumor suppressor was investigated as a competing endogenous RNA for miR-574-5p.	23599737	Lnc2Cancer
EL1102	PVT1	thyroid cancer	qPCR, Western blot, RIP, ChIP etc.	thyroid cancer tissues, cell lines (IHH-4, FTC-133, 8505C)	up-regulated	interaction	Compared to the controls, lncRNA PVT1 was significantly up-regulated in thyroid tissues, as well as in three kinds of tumor cell lines (P < 0.05). Silenced PVT1 significantly inhibited thyroid cell line IHH-4, FTC-133, and 8505C cell proliferation and arrested cell cycle at G0/G1 stage and significantly decreased cyclin D1 and TSHR expressions (P < 0.05). Moreover, lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2	26427660	Lnc2Cancer